Post-marketing surveillance of Vadadustat in patients with anemia in chronic kidney disease for long-term efficacy and safety

Post-marketing surveillance of Vadadustat in patients with anemia in chronic kidney disease for long-term efficacy and safety - VIOLET survey

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042349

Enrollment

2000

Registered

2020-11-24

Start date

2020-11-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal anemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with renal anemia who receive Vafseo tablets for the first time

Exclusion criteria

Exclusion criteria: Patients scheduled to undergo renal transplantation are excluded from the surveillance, but those registered on the waiting list for renal transplantation may be eligible

Design outcomes

Primary

Measure	Time frame
Safety Occurrence of adverse events during the observation period Efficacy Time course of the hemoglobin level during the observation period	—

Countries

Japan

Contacts

Public ContactMihoko Hata

Tanabe Pharma Corporation Pharmacovigilance Department

tp-pms-shinchoku.JP@ml.tanabe-pharma.com03-6743-7733

Outcome results